Raphael Catane

9.2k total citations · 2 hit papers
133 papers, 7.2k citations indexed

About

Raphael Catane is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Raphael Catane has authored 133 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Raphael Catane's work include Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (12 papers) and BRCA gene mutations in cancer (11 papers). Raphael Catane is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (12 papers) and BRCA gene mutations in cancer (11 papers). Raphael Catane collaborates with scholars based in Israel, United States and Germany. Raphael Catane's co-authors include Bella Kaufman, Beatrice Uziely, Alberto Gabizón, Nathan I. Cherny, Rivka Cohen, Anthony H. C. Huang, Bela Kaufman, Y. Barenholz, Tamar Safra and Francisco J. Plaza Martín and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Raphael Catane

131 papers receiving 6.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 1.3k citations E O’Brien, Nely Wigler et al. Annals of Oncology profile →
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

1994 1.2k citations Raphael Catane et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Raphael Catane	2.5k	2.1k	1.5k	1.2k	957	133	7.2k
Giuseppe Toffoli	3.1k 1.2×	3.9k 1.9×	812 0.6×	1.0k 0.8×	922 1.0×	337	8.8k
O. Michael Colvin	1.9k 0.8×	2.5k 1.2×	822 0.6×	926 0.8×	674 0.7×	124	7.0k
Sang Yoon Kim	2.0k 0.8×	2.4k 1.2×	1.1k 0.7×	893 0.7×	785 0.8×	224	7.2k
Noriaki Ohuchi	3.4k 1.4×	3.1k 1.5×	448 0.3×	729 0.6×	1.4k 1.4×	388	9.8k
Christoph Rochlitz	3.6k 1.4×	2.1k 1.0×	338 0.2×	576 0.5×	800 0.8×	137	6.5k
Beatrice Uziely	1.5k 0.6×	1.3k 0.6×	1.1k 0.8×	589 0.5×	439 0.5×	83	4.6k
Robert D. Simari	861 0.3×	3.0k 1.5×	733 0.5×	469 0.4×	954 1.0×	164	7.8k
Donald W. Northfelt	3.2k 1.3×	1.4k 0.7×	541 0.4×	405 0.3×	978 1.0×	212	6.0k
William C. Zamboni	2.4k 1.0×	3.3k 1.6×	3.1k 2.1×	2.4k 2.0×	1.0k 1.1×	202	8.0k
Michael V. Seiden	4.1k 1.6×	3.0k 1.5×	504 0.3×	369 0.3×	1.4k 1.4×	172	8.5k

Countries citing papers authored by Raphael Catane

Since Specialization

Citations

This map shows the geographic impact of Raphael Catane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Catane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Catane more than expected).

Fields of papers citing papers by Raphael Catane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Catane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Catane. The network helps show where Raphael Catane may publish in the future.

Co-authorship network of co-authors of Raphael Catane

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Catane. A scholar is included among the top collaborators of Raphael Catane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Catane. Raphael Catane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paluch–Shimon, Shani, Eitan Friedman, Raanan Berger, et al.. (2016). Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Research and Treatment. 157(1). 157–165. 31 indexed citations

Besser, Michal J., Ronnie Shapira‐Frommer, Avraham J. Treves, et al.. (2010). Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research. 16(9). 2646–2655. 352 indexed citations

Paluch–Shimon, Shani, Noa Ben-Baruch, Ido Wolf, et al.. (2009). Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients. American Journal of Clinical Oncology. 32(5). 504–508. 10 indexed citations

Cherny, Nathan I., et al.. (2009). European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive program. Annals of Oncology. 21(2). 362–369. 71 indexed citations

Wolf, Ingo, Yael Laitman, Tamar Rubinek, et al.. (2009). Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene. 29(1). 26–33. 40 indexed citations

Paluch–Shimon, Shani, Ido Wolf, Hadassah Goldberg, et al.. (2008). High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer. Acta Oncologica. 47(8). 1564–1569. 11 indexed citations

Symon, Zvi, Tatiana Rabin, D. Alezra, et al.. (2006). 2133. International Journal of Radiation Oncology*Biology*Physics. 66(3). S284–S285. 4 indexed citations

Catane, Raphael, Alexander Beck, Yael Inbar, et al.. (2006). MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases—preliminary clinical experience. Annals of Oncology. 18(1). 163–167. 196 indexed citations

Wolf, Ido, Siegal Sadetzki, Raphael Catane, Avraham Karasik, & Bella Kaufman. (2005). Diabetes mellitus and breast cancer. The Lancet Oncology. 6(2). 103–111. 324 indexed citations

10.

O’Brien, E, Nely Wigler, Moshe Inbar, et al.. (2004). Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of Oncology. 15(3). 440–449. 1311 indexed citations breakdown →

11.

Ron, Ilan G., Nely Wigler, Riva Borovik, et al.. (2002). CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer. American Journal of Clinical Oncology. 25(5). 520–522. 1 indexed citations

12.

Ron, Ilan G., Nely Wigler, Riva Borovik, et al.. (2001). CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer. American Journal of Clinical Oncology. 24(4). 323–327. 7 indexed citations

13.

Sapir, Rama, et al.. (1999). Cancer Pain. Journal of Pain and Symptom Management. 17(4). 266–276. 50 indexed citations

14.

Haim, Nissim, et al.. (1993). Estimation of Creatinine Clearance Without 24-Hour Urine Collection—A Useful Guide During Cisplatin Therapy. Acta Oncologica. 32(4). 409–412. 15 indexed citations

15.

Siegal, Tali, et al.. (1988). Early and delayed neurotoxicity of Mitoxantrone and Doxorubicin following subarachnoid injection. Journal of Neuro-Oncology. 6(2). 135–140. 5 indexed citations

16.

Siegal, Tzony, et al.. (1988). Indomethacin and Dexamethasone Treatment in Experimental Neoplastic Spinal Cord Compression: Part 1. Neurosurgery. 22(2). 328–333. 19 indexed citations

17.

Didolkar, Mukund S., Raphael Catane, Renata Fonseca Vianna Lopez, & E. Douglas Holyoke. (1978). Estramustine phosphate (estracyt) in advanced malignant melanoma resistant to DTIC treatment. Proceedings of the American Association for Cancer Research. 19. 3 indexed citations

18.

Mittelman, A, Raphael Catane, & G.P. Murphy. (1977). New steroidal alkylating agents in advanced stage D carcinoma of the prostate.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(2). 307–10. 8 indexed citations

19.

Catane, Raphael, et al.. (1977). Preliminary clinical study of prednimustine in lung cancer.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(2). 115–21. 3 indexed citations

20.

Catane, Raphael, H. O. Douglass, & A Mittelman. (1977). A phase II study of high dose cis diammine dichloro platinum II (DDP) in non testicular tumors. Proceedings of the American Association for Cancer Research. 18. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact